sameAs
Prolyl-4-Hydroxylases Inhibitor Stabilizes HIF-1α and Increases Mitophagy to Reduce Cell Death After Experimental Retinal DetachmentRandomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis PatientsComparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study.Hypoxia enhances tenocyte differentiation of adipose-derived mesenchymal stem cells by inducing hypoxia-inducible factor-1α in a co-culture system.Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury.Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case.A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving DialysisRoxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialEvaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese SubjectsSafety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis PatientsPost-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Dialysis-dependent Patients With Renal Anemia
P921
Q28854320-87DFB129-570D-4643-806E-F8111C9140A5Q36058555-D1625986-EAAD-4C01-856A-AC542B14F2AFQ36746098-01C2F7BC-77B1-4E6A-AA38-383140D8E99DQ37173066-E72EA8FE-20C3-4DCC-BAA7-F8E1C1A3AB5DQ37180873-EBF055F0-8B89-4EDD-8198-A5176CDF1C03Q38395144-636758BF-E954-4AA9-9B70-85394E915114Q38782787-043FA6A6-A670-4702-A946-228CD2A391C0Q41823201-EEA26D5A-A7AE-4A33-A235-A25E4DE26E53Q48691036-C8F1A97D-FCF9-4E82-AB8B-02E4BC8E5D5AQ49094854-CDF6953D-0737-4B40-A025-1042D36829D3Q55059553-62DB6638-04FD-4133-B4B7-536535F502A5Q63840810-814B995B-9188-4D71-8D5B-E2B40064BD11Q64111741-D8B28391-41F3-4D15-A0BF-217B038A743DQ64123950-FCAEDA82-1AD0-4EF9-AD63-3E98867EFE88Q64336726-1416E8FD-1DAD-4425-8F73-3997AA702E79Q95799309-B081F92E-802C-4C12-92DE-E4170D7C2AC0Q95799309-C718E901-79C4-46E3-87D2-338140D0806C
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Roxadustat
@de
roxadustat
@en
type
label
Roxadustat
@de
roxadustat
@en
altLabel
ASP-1517
@en
ASP1517
@en
AZD9941
@en
FG 4592
@en
FG-4592
@en
FG4592
@en
HIF prolyl-hydroxylase inhibitor
@en
Roxadustat
@en
prefLabel
Roxadustat
@de
roxadustat
@en
P592
P661
P662
P665
P683
P117
P1579
P2067
352.105922
P2275
roxadustat
@en
P231
808118-40-3
P232
P233
CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O
P234
1S/C19H16N2O5/c1-11-15-9-13(26 ...... 4H,10H2,1H3,(H,20,25)(H,22,23)
P235
YOZBGTLTNGAVFU-UHFFFAOYSA-N
P2566
100.245.356
P267
P274
C₁₉H₁₆N₂O₅
P3117
DTXSID60230644
P592
CHEMBL2338329
P652
X3O30D9YMX